2019 American Transplant Congress
Assessing the Effectiveness of Early Maintenance Immunosuppression Practices in Liver Transplantation
University of Pennsylvania, Philadelphia, PA
*Purpose: Evidence regarding the efficacy of maintenance immunosuppression (IS) regimens for liver transplantation (LT) arise from clinical trials. However, the ‘real world’ effectiveness of such…2019 American Transplant Congress
Assessing Discarded Human Liver Quality with Normothermic Ex-Vivo Liver Perfusion
Surgery, Washington University in St. Louis, St. Louis, MO
*Purpose: Normothermic Ex-vivo Liver Perfusion (NELP) of livers shows promising results in overcoming injuries that occur in deceased donor liver transplantation. The effect of NELP…2019 American Transplant Congress
Development and Validation of a Capillary Blood Mitra-Based Assay for the Quantitative Determination of Advagraf® Concentrations in Transplant Patients
*Purpose: Therapeutic drug monitoring of tacrolimus (TAC) requires venepuncture blood samples taken by specialists, requiring patients to attend an outpatient clinic; this can be inconvenient…2019 American Transplant Congress
Results of Litmus (nct 02541916): The Liver Immune Tolerance Bio Marker Utilization Study
*Purpose: Previously we reported a novel biomarker gene set for the identification of tolerance in murine models of rapamycin-induced cardiac tolerance and spontaneous hepatic tolerance.…2019 American Transplant Congress
Alcohol Recidivism In Liver Transplant Recipients With Alcoholic Liver Disease: Does Six-months Abstinence Rule Still Holds True?
1UTHSC, Memphis, TN, 2University of Memphis, Memphis, TN
*Purpose: Liver transplant for alcoholic liver disease (ALD) continues to be a challenge for transplant centers, particularly related to the ethical dilemma of transplanting or…2019 American Transplant Congress
Global and Domain Specific Cognition in Liver Transplant Recipients
*Purpose: Liver transplant (LT) recipients may experience global or domain-specific cognitive impairment (CI) (e.g., attention and memory) post-transplant due to multiple potential factors such as…2019 American Transplant Congress
Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was designed to compare efficacy and safety of earlyuse of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus Standard tacrolimus [TAC-C)…2019 American Transplant Congress
Post-Reperfusion Hepatic Beta-Catenin Activation Regulates Graft Damage, Inflammatory Responses and Transplant Outcomes
Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA
*Purpose: Hepatic ischemia-reperfusion injury (IRI), an innate-immune driven hepatic inflammation response, represents a major risk factor of early allograft dysfunction (EAD) and rejection in liver…2019 American Transplant Congress
Does Secondary Simultaneous Liver Kidney versus Liver Alone Make a Difference in Terms of Patient and Graft Survival
University of Wisconsin, Madison, WI
*Purpose: Survival benefits have been shown with primary simultaneous liver kidney (SLK) transplantation as well as kidney after primary liver transplant when patients develop kidney…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 180
- Next Page »